CompanyHealthHardware
Marea Therapeutics
Marea Therapeutics is a clinical-stage biotechnology company in San Francisco developing first-in-class medicines for cardioendocrine and cardiometabolic diseases. Incubated by Third Rock Ventures and led by Dr. Josh Lehrer, Marea uses human genetics insights to drive its pipeline, headlined by MAR001, an ANGPTL4-targeting antibody aimed at residual cardiovascular risk, and MAR002 for acromegaly.
2023Founded
San FranciscoHQ
$142.5MSeries B
biotechcardiometaboliccardioendocrinedrug discoverymonoclonal antibodyangptl4